Biotech Networks
@BiotechNetworks
Followers
576
Following
48
Media
324
Statuses
9K
Connecting life scientists and professionals since 2008, with hubs across the US. @sdbn @sfbionetwork @bcbionetwork @dcbionetwork #biotech #news #jobs #events
San Diego, CA
Joined November 2021
.@UCBionetworks Trending News: Fake News: Medical Quackery Enters a New Dimension https://t.co/0uInPyYmie
#biotech #News
0
0
0
.@PNBionetwork Trending News: BREAKING: FDA advisors say in 6-4 vote that Amylyx's ALS drug is not effective. What will the agency do? https://t.co/LISG7NfoPR
#biotech #News
0
0
0
.@MWBionetworks Trending News: Nystrom & Associates Brands Unite Under New Name: Sagent Behavioral Health https://t.co/m1UsM6uSZ4
#biotech #News
0
0
0
.@MWBionetworks Trending News: Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors https://t.co/b9iv0l0Pee
#biotech #News
0
0
0
.@PNBionetwork Trending News: Doylestown Hospital discloses sale price for Pine Run Retirement Community https://t.co/UBhWCRMtPa
#News #biotech
0
0
0
.@DCBionetwork Trending News: Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed https://t.co/ZUwJd1kkKG
#News #biotech
0
0
0
.@PNBionetwork Trending News: Walgreens launches free Paxlovid delivery with DoorDash and Uber https://t.co/WiOK8btJUu
#News #biotech
0
0
0
.@MWBionetworks Trending News: Philly is on Lilly's radar for next Gateway Labs site https://t.co/O0JPBC2Cbt
#biotech #News
0
0
0
.@SDBN Trending News: BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society https://t.co/vXzGnBMNPg
#News #biotech
0
0
0
.@LABionetwork Trending News: Cherokee Uniforms Unveils New Line of Innovative, Fashion-Forward Medical Garments https://t.co/kt3Iwqyk6L
#News #biotech
labn.org
The Cherokee Collection emphasizes affordability and features industry-leading technology designed to keep healthcare professionals safe and stylish on the job. SANTA MONICA, Calif., May 11, 2023...
0
0
0
.@SDBN Trending News: How HIV’s shape-shifting protein reveals clues for smarter drug design https://t.co/s9h2q90BNn
#News #biotech
0
0
0
.@PNBionetwork Trending News: Pfizer spinout SpringWorks gets FDA priority review for lead drug https://t.co/87QNbQZlov
#News #biotech
0
0
0
.@DCBionetwork Trending News: REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF) https://t.co/zPlhJRF8cT
#News #biotech
0
0
0
.@FGBionetworks Trending News: Qualified Data Systems (QDS) Announces Spin-Off from BioTeknica https://t.co/B8ohBoN6lN
#News #biotech
0
0
0
.@BCBionetwork Trending News: Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio https://t.co/wIQCBebg4E
#biotech #News
0
0
0
.@DCBionetwork Trending News: NSTA’s Science and Children Journal Welcomes New Field Editor https://t.co/SJvrGdYCsV
#News #biotech
0
0
0
.@WOBionetworks Trending News: YorLabs Announces FDA 510(k) Clearance of its Zero-CapEx Intracardiac Imaging System https://t.co/5p7o8sZBOa
#biotech #News
0
0
0
.@SFBionetwork Trending News: RAPT Therapeutics Announces Proposed Public Offering of Common Stock https://t.co/jxslRDshA6
#biotech #News
sfbn.org
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering,...
0
0
0
.@SFBionetwork Trending News: Nurix targets $250 million stock sale to back pivotal study of leukemia drug https://t.co/iSa0ukb2Wi
#biotech #News
sfbn.org
Bexobrutideg could win FDA approval if a mid-stage trial shows the drug does what Nurix leaders think it can do against chronic lymphocytic leukemia. Click here to view original post Click Here to...
0
0
0
.@LABionetwork Trending News: A new player enters the KRAS game with Fortress; Gilead picks up once-failed cancer drug from Mologen's fire sale https://t.co/qFJQP2e5we
#biotech #News
labn.org
→ A new player is entering the KRAS race. The incubator Fortress Biotech has licensed a treatment developed at Columbia University by Jeffrey Rothman and Gary Schwartz and spun into a new company...
0
0
0